PFO
ALXN

Pathstone Family Office’s Alexion Pharmaceuticals ALXN Stock Holding History

Pathstone Family Office’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-842
Closed -$131K – 1490
2020
Q4 		$131K Buy
842
+755
+868% +$97K 0.01% 339
2020
Q3 		$10K Hold
87
– – ﹤0.01% 607
2020
Q2 		$10K Sell
87
-230
-73% -$24.4K ﹤0.01% 526
2020
Q1 		$29K Buy
317
+87
+38% +$8.54K ﹤0.01% 379
2019
Q4 		$249K Hold
230
– – ﹤0.01% 388
2019
Q3 		$23K Hold
230
– – ﹤0.01% 379
2019
Q2 		$30K Hold
230
– – ﹤0.01% 400
2019
Q1 		$31K Buy
+230
New +$28.6K ﹤0.01% 373
2017
Q2 		– Sell
-12
Closed -$1K – 688
2017
Q1 		$1K Buy
+12
New +$1.55K ﹤0.01% 547
2013
Q3 		– Sell
-23
Closed -$2K – 459
2013
Q2 		$2K Buy
+23
New +$2.22K ﹤0.01% 346

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $7.94B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $4.65B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return